Integrated Pharmacokinetic-Driven Approach to Screen Candidate Anticancer Drugs for Brain Tumor Chemotherapy

@article{Lv2012IntegratedPA,
  title={Integrated Pharmacokinetic-Driven Approach to Screen Candidate Anticancer Drugs for Brain Tumor Chemotherapy},
  author={Hua Wen Lv and Xiaoping Zhang and Jyoti Sharma and Mula Venkata Ramana Reddy and E. P. Reddy and James Michael. Gallo},
  journal={The AAPS Journal},
  year={2012},
  volume={15},
  pages={250-257}
}
The goal of the study was to develop an effective screening strategy to select new agents for brain tumor chemotherapy from a series of low molecular weight anticancer agents [ON123x] by the combined use of in silico, in vitro cytotoxicity, and in vitro ADME profiling studies. The results of these studies were cast into a pipeline of tier 1 and tier 2 procedures that resulted in the identification of ON123300 as the lead compound. Of the 154 ON123xx compounds, 13 met tier 1 screening criteria… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-6 OF 6 CITATIONS

Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models.

  • Molecular cancer therapeutics
  • 2014
VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier.

  • International journal of pharmaceutics
  • 2005
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Assessing brain free fraction in early drug discovery.

  • Expert opinion on drug metabolism & toxicology
  • 2010
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…